Valuation : Theralase Technologies Inc.

Market Cap 54.7M 39.39M 33.81M 31.73M 28.98M 3.76B 54.96M 376M 146M 1.9B 148M 145M 6.28B P/E 2026 *
-18.5x
P/E 2027 * 9.25x
Enterprise Value 54.7M 39.39M 33.81M 31.73M 28.98M 3.76B 54.96M 376M 146M 1.9B 148M 145M 6.28B EV / Sales 2026 *
68.2x
EV / Sales 2027 * 1.61x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 day-2.70%
1 week-5.26%
Current month-36.84%
1 month-30.77%
3 months-20.00%
6 months-36.84%
Current year+9.09%
1 week 0.18
Extreme 0.18
0.2
1 month 0.18
Extreme 0.175
0.3
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
07/08/26 Option

Director

1,000,000 0.3382%
07/08/26 Option

Chief Executive Officer

1,000,000 0.3382%
07/08/26 Option

Director

1,000,000 0.3382%
Change 5-day change 1-year change 3-year change Capi.($)
-2.70%-5.26%-16.28%-26.53% 39.39M
-1.18%-0.33%+26.02%+40.43% 1.43B
-0.43%-3.36%-31.34%-51.06% 266M
-2.37%-8.04%-25.90%-35.62% 52.22M
Average -1.67%-0.69%-11.87%-18.20% 446.3M
Weighted average by Cap. -1.14%-0.07%+15.03%+23.10%

Financials

2026 *2027 *
Net sales 802K 578K 496K 465K 425K 55.09M 806K 5.51M 2.13M 27.79M 2.17M 2.12M 92.05M 33.89M 24.4M 20.95M 19.66M 17.96M 2.33B 34.05M 233M 90.17M 1.17B 91.63M 89.64M 3.89B
Net income -4.2M -3.02M -2.6M -2.44M -2.23M -288M -4.22M -28.84M -11.18M -146M -11.36M -11.11M -482M 6.83M 4.92M 4.22M 3.96M 3.62M 469M 6.86M 46.9M 18.18M 237M 18.47M 18.07M 784M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
27/08/26 CA$0.1800 -2.70% 216,077
26/08/26 CA$0.1850 -2.63% 496,508
25/08/26 CA$0.1900 0.00% 559,121
24/08/26 CA$0.1900 +2.70% 326,571
21/08/26 CA$0.1850 -2.63% 344,702
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1850CAD
Average target price
0.7000CAD
Spread / Average Target
+278.38%

Quarterly revenue - Rate of surprise